Cable Hill Partners’s Editas Medicine EDIT Stock Holding History

Cable Hill Partners’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,000	Closed	-$23K	–	823
2018 Q4	$23K	Hold	1,000	–	–	0.01%	330
2018 Q3	$29K	Hold	1,000	–	–	0.01%	256
2018 Q2	$36K	Hold	1,000	–	–	0.02%	237
2018 Q1	$32K	Buy	+1,000	New	+$35.6K	0.01%	258

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Cable Hill Partners's EDIT Position: Q2 2019 in Review

Cable Hill Partners sold out of Editas Medicine (EDIT) in Q2 2019, closing a stake of 250 shares — an estimated $6K sold.

Cable Hill Partners first reported a position in EDIT in Q2 2016 and held it in 12 quarters. The position peaked at $12K in Q4 2017. 193 funds tracked by Wall St. Rank hold EDIT as of Q2 2019.

Cable Hill Partners reported no remaining Editas Medicine position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 250 Editas Medicine shares in Q2 2019, an estimated $6K.
Cable Hill Partners first reported a position in Editas Medicine in Q2 2016 and held it in 12 quarters.
Cable Hill Partners's Editas Medicine position peaked at $12K in Q4 2017.
193 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.